PIA
ATRS

Piedmont Investment Advisors’s Antares Pharma, Inc. ATRS Stock Holding History

Piedmont Investment Advisors’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,507
Closed -$6K – 2576
2018
Q2 		$6K Buy
+2,507
New +$6.24K ﹤0.01% 2068

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Piedmont Investment Advisors's ATRS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Antares Pharma, Inc. (ATRS) in Q3 2018, closing a stake of 2,507 shares — an estimated $6K sold.

Piedmont Investment Advisors first reported a position in ATRS in Q2 2018 and held it in 1 quarter. The position peaked at $6K in Q2 2018. 105 funds tracked by Wall St. Rank hold ATRS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Antares Pharma, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 2,507 Antares Pharma, Inc. shares in Q3 2018, an estimated $6K.
  • Piedmont Investment Advisors first reported a position in Antares Pharma, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Antares Pharma, Inc. position peaked at $6K in Q2 2018.
  • 105 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.